Lung Cancer Clinical Trials in Los Angeles

Showing 201-220 of 509 trials

Medical Access Program for Patritumab Deruxtecan

NCT06099639

The purpose of this Medical Access Program is to provide access to HER3-DXd for eligible patients with NSCLC who, in their treating physician's opinion, have an unmet clinical need which cannot be treated with approved and commercially available drugs and who cannot enter a clinical trial prior to commercial availability.

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

Daiichi Sankyo

Springdale, Arkansas, United States • Los Angeles, California, United States • Aurora, Colorado, United States +18 more locations

COMPLETEDPhase 2< 1 mile

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationLoss of Heterozygosity+8 more

SWOG Cancer Research Network64 participantsStarted Apr 2019

Mobile, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +947 more locations

Medical Access Program for Patritumab Deruxtecan

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Lung Cancer Trials in Other Cities

Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

Study of LP-184 in Patients With Advanced Solid Tumors

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Other Conditions in Los Angeles